

(51) International Patent Classification ⁶ : C12N 5/10, 15/85, 9/12, 15/54, 15/12, C07K 14/47, G01N 33/50		A2	(11) International Publication Number: WO 99/55844 (43) International Publication Date: 4 November 1999 (04.11.99)
(21) International Application Number: PCT/US99/09102 (22) International Filing Date: 27 April 1999 (27.04.99) (30) Priority Data: 09/067,284 27 April 1998 (27.04.98) US (71) Applicants: ICOS CORPORATION [US/US]; 22021 20th Avenue, S.E., Bothell, WA 98021 (US). OREGON HEALTH SCIENCE UNIVERSITY [US/US]; 3181 Southwest Sam Jackson Park Road, Portland, OR 97201 (US). (72) Inventors: HOEKSTRA, Merl, F.; 10321 216th Street, S.E., Snohomish, WA 98290 (US). THAYER, Matthew, J.; 2954 N.W. Savier Street, Portland, OR 97210 (US). (74) Agent: WILLIAMS, Joseph, A., Jr.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606-6402 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: METHODS FOR MODULATING DIFFERENTIATION			
(57) Abstract This invention generally relates to materials and methods for modulating the differentiation of cells. Specifically provided are methods to promote or inhibit cell differentiation and methods to identify compounds that promote cellular differentiation.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHODS FOR MODULATING DIFFERENTIATION

5

Background of the Invention

Rhabdomyosarcomas are highly malignant tumors composed of primitive muscle cells (stem cells) having a low propensity to differentiate. Cells of this type are grouped by histologic and cytogenetic criteria as either embryonal or alveolar rhabdomyosarcomas. The two types are distinguished by detection in embryonal
10 rhabdomyosarcomas of a loss of heterozygosity on the short arm of chromosome 11 encompassing 11p15.5 [Mitchell *et al.*, *Oncogene*, 6:89-92 (1991)] and in alveolar rhabdomyosarcomas, of a balanced translocation between chromosomes 2 and 13, t(2:13)(q35;q14) [Barr *et al.*, *Nat. Genet.*, 3:113-117 (1993)]. Loss of heterozygosity at 11p15.5 is also associated with a number of other solid tumors [Newsham *et al.*, *Genes*
15 *Chromosom. Cancer*, 3:108-116 (1991)] suggesting the location of a tumor suppressor gene(s) for multiple tumor types in this region.

In tumor cells, expression of the muscle differentiation factor MyoD [Weintraub, H., *Cell*, 75:1241-1244 (1993)] has been shown to be a highly sensitive marker for classifying sarcomas as rhabdomyosarcomas [Dias *et al.*, *Am. J. Pathol.*,
20 137:1283-1291 (1990); Scrable *et al.*, *Proc. Natl. Acad. Sci., USA*, 87:2182-2186 (1990)]. MyoD is a member of a large family of transcription factors that belong to the basic-helix-loop-helix (BHLH) family known to control cell fate determination and stem cell function. While MyoD is associated with myoblast differentiation, related proteins determine the fate of other primitive cell types. For example, SCL controls
25 hematopoietic stem cell differentiation [Porcher, *et al.*, *Cell* 86:47-57 (1996)] and neurogenic stem cell differentiation is controlled by the BHLH proteins MASH, neurogenin, and neuro D [Reviewed in Morrison *et al.*, *Cell* 88:287-298 (1997) and Andersen, *FASEB J.*, 8:707-713 (1994)]. Similarly, liver stem cell differentiation is regulated by a combination of transcription factors including NF- κ B, Stat3, and C/EBP
30 [Taub, *FASEB J.* 10:413-427 (1996)]. Conversely, expression of transforming oncogenes inhibits cellular differentiation in several different cell lineages [Holtzer *et al.*, *Proc. Natl.*

-2-

5 *Acad. Sci. USA*, 72:4051-4055 (1975); Lassar *et al.*, *Cell*, 58:659-667 (1989)]. In muscle cells, for example, expression of oncogenic tyrosine kinases (v-src and v-fps), growth factor receptors (v-erbB), nuclear oncogenes (v-myc, c-myc, v-erbA, E1A, and MDM2), and the activated form of signal transducing G proteins (H-ras and N-ras) can inhibit terminal differentiation to varying degrees [Fizman and Fuchs, *Nature*, 254:429-431 (1975); Holtzer *et al.*, *Proc. Natl. Acad. Sci. USA*, 72:4051-4055 (1975); Fiddler *et al.*, *Mol. Cell Biol.* 16:5048-5057 (1996)]. The paradox that MyoD, shown to induce muscle differentiation in a wide variety of primary cells and transformed cell lines [Weintraub *et al.*, *Proc. Natl. Acad. Sci.*, 86:5434-5438 (1989)], serves as a hallmark for identification of a particular tumor type may be resolved by the possibility that MyoD appears to be non-functional in the neoplastic cells.

15 In rhabdomyosarcomas, abnormalities in protein expression have been reported, including for example, p53 and ras expression [Hiti *et al.*, *Mol. Cell Biol.*, 9:4722-4730 (1989); Dias *et al.*, *Am. J. Pathol.*, 137:1283-1291 (1990); Loh *et al.* *Proc. Natl. Acad. Sci. USA*, 89:1755-1759 (1992)], however, the loci involved in the 11p loss of heterozygosity have not been identified. It is clear, however, that MyoD expression is unaffected [Scrable *et al.*, *Proc. Natl. Acad. Sci., USA*, 87:2182-2186 (1990)]. Chromosome transfer experiments wherein a normal chromosome 11 was introduced into rhabdomyosarcoma cells resulted in inhibition of cell growth and tumor formation in nude mice but had no effect on myogenic differentiation [Loh *et al.*, *Proc. Natl. Acad. Sci. USA*, 89:1755-1759 (1992)]. Thus, the loss of the chromosome 11 locus was shown not to be responsible for the lack of differentiation in embryonal rhabdomyosarcomas.

25 One obvious phenotype of rhabdomyosarcomas is a lack of terminal differentiation and somatic cell genetic experiments have been carried out in attempts to identify genetic loci present in rhabdomyosarcoma cells that inhibit muscle differentiation. Results indicated that rhabdomyosarcomas could be classified by cell fusion experiments as either recessive or dominant with respect to their inability to differentiate [Tapscott *et al.*, *Science*, 259:1450-1453 (1993)]. Furthermore, transfer of a derivative chromosome 14 from the rhabdomyosarcoma cell line Rh18, a cell type that displays a dominant non-differentiating phenotype, into the differentiation competent myoblast cell line C2C12 inhibited muscle differentiation as well as the ability of MyoD to transactivate reporter

30

-3-

constructs. The derivative chromosome 14 contained amplified DNA originating from chromosome 12q13-14, a region containing several genes often amplified in sarcomas. Testing the amplified genes for the ability to inhibit muscle-specific gene expression indicated that forced expression of one gene in particular, Murine Double Minute Gene 2 (MDM2), inhibited MyoD function and consequently inhibited muscle differentiation [Fiddler *et al.*, *Mol. Cell Biol.* 16:5048-5057 (1996)]. MDM2 was originally identified in a spontaneously transformed cell line [Fakharzadeh *et al.*, *EMBO J.*, 10:1565-1569 (1991)] and was subsequently shown to interact with p53 [Oliner *et al.*, *Nature*, 358:80 (1992)].

In addition to the above chromosomal abnormalities, chromosome 3q alterations have been found to occur frequently in rhabdomyosarcomas. Previous studies have shown that gain of 3q was present in two out of ten embryonal rhabdomyosarcomas [Weber-Hall *et al.*, *Cancer Res.*, 56:3220-3224 (1996)]. In addition, gain of 3q has been observed at high frequency in several other types of tumors, including, for example, 52% of prostate tumors [Cher *et al.*, *Cancer Res.*, 56:3091-3102 (1996)], ten out of thirteen small cell lung carcinomas [Ried *et al.*, *Cancer Res.*, 54:1801-1806 (1994)], ten out of thirteen head and neck squamous cell carcinomas [Speicher *et al.*, *Cancer Res.*, 55:1010-1013 (1995)], and nine out of ten cervical carcinomas [Heselmeyer *et al.*, *Proc. Natl. Acad. Sci. USA*, 93:479-484 (1996)]. Furthermore, the gain of chromosome 3q by isochromosome formation in HPV16-infected cells defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix [Heselmeyer *et al.*, *Proc. Natl. Acad. Sci. USA*, 93:479-484 (1996)].

Even though the precise consequences of the various rhabdomyosarcoma genetic changes are unclear, the chromosomal rearrangement/damage is consistent with the belief that tumorigenesis is a multistep process with genetic damage occurring in most, if not all, cancer cells [Bishop, J. M., *Science*, 235:305-311 (1987)]. Whatever the precise mechanism involved, the prevalence of DNA damage in numerous cancer cells brings into question the role of cell cycle checkpoints in neoplastic cell types. Cell cycle checkpoints consist of signal transduction cascades which couple DNA damage detection to cell cycle progression, and failure of one or more components in the system predisposes an individual to, or directly causes, many disease states such as cancer, ataxia telangiectasia,

embryo abnormalities, and various immunological defects associated with aberrant B and T cell development. Polypeptides of the checkpoint system play roles in detecting and signaling a response to DNA damage that occurs as a result of replication errors, DNA mismatches, radiation damage, or chemotherapy.

5 It has been proposed that cell cycle checkpoints comprise at least three distinct classes of polypeptides which act sequentially in response to cell cycle signals or defects in chromosomal mechanisms [Carr, A.M., *Science*, 271:314-315 (1996)]. The first class of proteins, exemplified by ATM [Rotman and Shiloh, *Cancer Surv.* 29:285-304 (1997)] and ATR [Keegan *et al.*, *Genes and Devel.*, 10:2423-2437 (1996)], detect or
10 sense DNA damage or abnormalities. The second class of polypeptides, exemplified by Rad53 [Flaggs *et al.*, *Current Biology*, (1997)], amplifies and transmits signals from the detector polypeptides. Finally, effector polypeptides, exemplified by mammalian p53, yeast wee1, *S. pombe* CHK1, [Al-Khodairy *et al.*, *Mol. Biol. Cell*, 5:147-160 (1994)], and human CHK1, bring about an appropriate cellular response, *e.g.* arrest of mitosis/meiosis
15 or apoptosis.

 Despite the roles for the checkpoint system to properly manage DNA damage and/or abnormalities, it is unclear what, if any relationship exists between the checkpoint system and neoplastic growth that results, at least in part, from genetic damage and/or rearrangement. More importantly, the art is silent with respect to what, if any
20 relationship exists between expression of MyoD and the checkpoint system.

 There thus is a need in the art for promoting differentiation of differentiation-inhibited cells such as rhabdomyosarcomas. More generally, there is also a need to modulate differentiation of other cells of interest. For example, inhibition of the differentiation of stem cells is contemplated so that the stem cell population may be
25 expanded for therapeutic manipulation.

Summary of the Invention

 The present invention provides materials and methods for modulating cellular differentiation. The invention embraces *in vitro*, *in vivo*, and *ex vivo* methods wherein differentiation of a particular cell type can be induced or inhibited. The invention
30 further contemplates methods and cell lines to identify compounds which induce or inhibit

-5-

cellular differentiation. Preferred cell amenable to the methods of the invention include germ cells and progenitor cells (as exemplified herein by stems cells, and the more fully differentiated myoblasts). As used herein and understood in the art, "progenitor cells" refer to any somatic cells that have the capacity to generate fully differentiated functional progeny by differentiation and proliferation. Progenitor cells include progenitors from any tissue or organ system, including but limited to blood, nerve, muscle, skin, gut, bone, kidney, liver, pancreas, thymus, and the like. Progenitor cells are distinguished from "differentiated cells", which are defined as those cells that may or may not have the capacity to proliferate, i.e., self replicate, but are unable to undergo further differentiation to a different cell type under normal physiological conditions. Moreover, progenitor cells are further distinguished from abnormal cells such as cancer cells, especially leukemia cells, which proliferate (self-replicate) but generally do not further differentiate, despite appearing to be immature or undifferentiated. Progenitor cells include all cells in a lineage of differentiation and proliferation prior to the most differentiated or the fully mature cell, including, for example, stem cells, the most primitive, "undifferentiated" progenitor cells and myoblasts, a cell type differentiated beyond a stem cell but not fully differentiated into a muscle cell.

In one aspect, the invention provides a method for inhibiting differentiation of a cell comprising the step of transforming or transfecting the cell with a polynucleotide encoding a cell cycle checkpoint protein. Cells inhibited in this manner can be expanded and are useful in therapeutic treatment of a variety of diseases requiring differentiation-inhibited cells including, for example, immunological diseases and diseases involving organ failure. Preferred cell types of the invention are either stably or transiently transformed or transfected with the cell cycle protein-encoding polynucleotide. Preferred cells contemplated in accordance with the invention are stem cells; more preferably cells of the invention are myoblasts. Other cell type contemplated by the invention include hematopoietic stem cells, neurogenic stem cells, liver stem cells, and germ cells. Preferred polynucleotides encode cell cycle checkpoint proteins ATR and CHK1 as well as other cell cycle checkpoint proteins including human isoforms of *S. pombe* Rad1, Rad17, Cds1, Rad9, and Hus1.

-6-

In one aspect, cells of the invention are transiently or stably transformed or transfected with a polynucleotide encoding a cell cycle checkpoint protein. A preferred cell of the invention is C2(Rh30)-2, deposited on April 21, 1998 with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110 and assigned
5 Accession Number CRL-12516. The introduction of polynucleotides encoding cell cycle checkpoint proteins can be accomplished by any of the multitude of methods well known and routinely practiced in the art, including, for example, precipitation techniques, electroporation, and vector-mediated transfection. In vector-mediated transformation or transfection, the preferred vector is a viral vector. Preferred cells of the invention are
10 stable transfectants.

As another aspect, the invention includes methods to identify compounds that enhance transcription from one or more polynucleotides encoding cell cycle checkpoint polypeptides, the method comprising the steps of (a) determining the degree of transcription of a checkpoint polynucleotide in a host cell in the presence and absence
15 of a test compound; (b) comparing the levels of transcription in (a); (c) identifying as a transcriptional enhancer a test compound that increases the level of transcription compared to transcription in the absence of the test compound. Host cells of the method include cells comprising endogenous genomic checkpoint polynucleotides, as well as host cells transformed or transfected with one or more polynucleotides encoding checkpoint
20 polypeptides. The invention further embraces transcriptional enhancers identified by methods of the invention. Methods to inhibit cell differentiation comprising the step of contacting a cell with a transcriptional enhancer of the invention are also contemplated.

Alternatively, the invention provides methods to identify compounds that enhance transcription from one or more reporter gene polynucleotides operatively linked
25 to a cell cycle checkpoint polynucleotide regulatory sequence, the method comprising the steps of (a) determining the levels of expression of a reporter gene operatively linked to regulatory sequences normally associated with transcriptional control of checkpoint gene in a host cell in the presence and absence of a test compound; (b) comparing the levels of expression in (a); (c) identifying as a transcriptional enhancer a test compound that
30 increases the level of reporter gene expression compared to the level of expression in the absence of the test compound. Host cells of the method include cells transformed or

-7-

transfected with cell cycle checkpoint regulatory polynucleotides operatively linked to any of a multitude of reporter gene well known and routinely utilized in the art. [See, for example, Ausubel, *et al.*, (Eds), Protocols in Molecular Biology, John Wiley & Sons (1994), pp 9.6.3 through 9.6.12.] The invention further embraces transcriptional enhancers identified by methods of the invention. The invention also embraces methods to inhibit cell differentiation comprising the step of contacting a cell with a transcriptional enhancer of the invention.

In another aspect, the invention provides methods to identify compounds that enhance biological activity of a cell cycle checkpoint polypeptide, the method comprising the steps of (a) determining the levels of activity of a checkpoint polynucleotide in a host cell in the presence and absence of a test compound; (b) comparing the levels of activity in (a); (c) identifying as an activity enhancer a test compound that increases the level of activity compared to the level of activity in the absence of the test compound. Host cells of the method include cells comprising endogenous genomic checkpoint polynucleotides, as well as host cells transformed or transfected with one or more polynucleotides encoding checkpoint polypeptides. The invention further embraces cell cycle checkpoint polypeptide activity enhancers identified by methods of the invention. The invention also includes methods to inhibit cell differentiation comprising the step of contacting a cell with an activity enhancer of the invention.

The invention further embraces methods to identify a compound that inhibits differentiation of a cell, said compound increasing transcription of a polynucleotide encoding a cell cycle checkpoint protein, said method comprising the steps of: a) determining the degree of differentiation of a cell line in the presence and absence of a test compound; b) comparing the degrees of differentiation in step (a); and c) identifying as an inhibitor of differentiation a test compound that reduces the degree of differentiation and increases the level of transcription of the polynucleotide encoding the cell cycle checkpoint protein compared to the degree of differentiation and level of transcription in the absence of the test compound. The method further contemplates compounds identified by the methods of the invention.

-8-

The invention further provides a method for inhibiting differentiation of a cell comprising the step of contacting the cell with a compound that increases transcription of a polynucleotide encoding a cell cycle checkpoint protein. Preferred cells of the method are stem cells. The invention, however, further embraces myoblasts, hematopoietic stem cells, neurogenic stem cells, liver stem cells and germ cells. The preferred checkpoint protein is ATR or CHK1.

The invention also provides a method to identify a compound that inhibits differentiation of a cell, said compound increasing biological activity of a cell cycle checkpoint protein, said method comprising the steps of: a) determining the degree of differentiation of a cell line in the presence and absence of a test compound; b) comparing the degrees of differentiation in step (a); and c) identifying as an inhibitor of differentiation a test compound that reduces the degree of differentiation and increases the biological activity of the cell cycle checkpoint protein compared to the degree of differentiation and biological activity in the absence of the test compound. The invention also embraces compounds identified by the method.

The invention also provides a method for inhibiting differentiation of a cell comprising the step of contacting the cell with a compound that increases biological activity of a cell cycle checkpoint protein. Preferred cells of the method are stem cells. Other cell types useful in the method include myoblasts, hematopoietic stem cells, neurogenic stem cells, liver stem cells and germ cells. The preferred checkpoint protein of the invention is ATR or CHK1.

Another aspect of the invention provides a method of promoting differentiation of a differentiation-inhibited cell comprising the step of contacting the cell with an inhibitor of a cell cycle checkpoint protein. In one aspect, the method embraces introducing into a cell a polynucleotide encoding a mutated cell cycle checkpoint polypeptide; the mutated polypeptide having a decreased biological activity thereby producing a dominant/negative phenotype in the cell. The invention provides a compounds which inhibit or reduce biological activity of the checkpoint protein.

In another aspect, the invention provides a method for promoting differentiation in a differentiation-inhibited cell comprising the step of contacting the cell with a compound that inhibits or reduces transcription of a polynucleotide encoding a cell

-9-

cycle checkpoint protein. Preferred differentiation-inhibited cell types are tumor cells. More preferred differentiation-inhibited cells include rhabdomyosarcomas and actively proliferating cancer cells including, for example, cervical carcinomas, small cell lung tumors, prostate tumors, squamous cell carcinomas. Cells amenable to use in the invention include those which are differentiation-inhibited by virtue of endogenous expression of a cell cycle checkpoint protein. Alternatively, cells can be modified by transformation to include a polynucleotide encoding one or more cell cycle checkpoint proteins. Cells also include those having increased copy number of one or more genes that maintain the differentiation-inhibited state, for example a rhabdomyosarcoma cell line having an isochromosome i(3q) resulting in an increase in copy number of the ATR gene. Differentiation of the differentiation-inhibited cells can be achieved by contacting the cells with an inhibitor of a cell cycle checkpoint protein or an inhibitor of a protein downstream in the checkpoint cascade. Alternatively, differentiation can be achieved by contacting the cell with a compound that inhibits transcription of (i) the cell cycle checkpoint protein, (ii) a transcription factor which acts to specifically increase transcription of the cell cycle protein, or (iii) a protein in a cell cycle checkpoint cascade modulated by a specific cell cycle protein. Conversely, exposing differentiated cells to increased cell cycle checkpoint proteins should revert these cells to a less differentiated, stem cell state or maintain a less differentiated, stem cell state for precursor cells.

Thus, the invention also provides methods for reverting differentiation of a differentiated cell comprising the step of contacting the differentiated cell with a compound that increases biological activity of a cell cycle checkpoint protein. In another aspect, the invention provides methods for reverting differentiation of a differentiated cell comprising the step of contacting the differentiated cell with a compound that increases transcription of a polynucleotide encoding a cell cycle checkpoint protein. In the preferred methods, the cell cycle checkpoint protein is selected from the group consisting of ATR and CHK1. In another aspect, the invention provides a method to revert differentiation of a muscle cell comprising the step of contacting the muscle cell with a compound that inhibits biological activity of MyoD.

The invention also comprehends methods for identifying a compound that promotes differentiation of a differentiation-inhibited cell, said compound inhibiting

-10-

biological activity of a cell cycle checkpoint protein; said method comprising the steps of:

5 a) determining the expression levels of a differentiation marker protein in said differentiation-inhibited cell in the absence and presence of the compound; b) comparing the expression levels of the differentiation marker determined in step (a); and c) identifying

10 as a promoter of differentiation a test compound that increases the expression level of the differentiation marker and inhibits biological activity of the cell cycle checkpoint protein compared to the level of expression of the marker and biological activity in the absence of the test compound. As an alternative, the invention also includes a method for identifying a compound that promotes differentiation of a differentiation-inhibited cell, said

15 compound inhibiting transcription of a polynucleotide encoding a cell cycle checkpoint protein; said method comprising the steps of: a) determining the expression levels of a differentiation marker protein in said differentiation-inhibited cell in the absence and presence of the compound; b) comparing the expression levels of the differentiation marker determined in step (a); and c) identifying as a promoter of differentiation a test

20 compound that increases the expression level of the differentiation marker and inhibits transcription of the polynucleotide encoding the cell cycle checkpoint protein compared to the expression level and transcription in the absence of the test compound. The invention further provide compounds identified by the methods. Preferred differentiation marker proteins of the methods are myosin heavy chain, MyoD, myogenin, and MLC/13. The invention further includes methods wherein the differentiation marker protein is SCL, MASH, neurogenin, neuroD, NF- κ B or Stat3. The preferred cell cycle checkpoint polypeptide is either ATR or CHK1.

The invention further provides methods for promoting differentiation of a differentiation-inhibited cell comprising the step of modifying an endogenous gene

25 sequence encoding a cell cycle checkpoint protein such that the cell expresses the cell cycle checkpoint protein at a reduced level. The targeted gene sequence can be modified in the protein coding region and/or in a transcriptional regulatory region. Modification of the polynucleotide can be effected in many ways. In one example, DNA encoding the cell cycle checkpoint protein is disrupted by insertions or deletions that result in a shift in

30 the reading frame to the extent that expression of an active protein is no longer possible. Disruption of the DNA can take place in a region that regulates expression of the protein

-11-

including promoter and/or enhancer sequences. Modification of the DNA in this manner can be effected by, for example, homologous recombination. See, for example, PCT International Publication No. WO 94/12650, PCT International Publication No. WO 92/20808, and PCT International Publication No. WO91/09955. Delivery of
5 polynucleotides which can disrupt sequences in a cell is effected *in vivo* or *ex vivo* by use of vectors, and more particularly viral vectors (*e.g.*, adenovirus, adeno-associated virus, or a retrovirus), or *ex vivo* by use of physical DNA transfer methods (*e.g.*, liposomes or chemical treatments). For reviews of gene therapy technology see Friedmann, *Science*, 244: 1275-1281 (1989); Verma, *Scientific American*: 68-84 (1990); and Miller, *Nature*,
10 357: 455-460 (1992).

As an alternative, modification of the cell cycle checkpoint polynucleotide can be affected by hybridization with antisense sequences. The invention therefore includes a method for promoting differentiation of a differentiation-inhibited cell comprising the step of introducing into a cell a first polynucleotide encoding an antisense
15 polynucleotide that hybridizes to a second polynucleotide encoding a cell cycle checkpoint protein. For a recent review of antisense therapy, see Delihias, *et al.*, *Nature Biotechnology* 15:751-753 (1997). It is intended that antisense therapy could be applied to negatively regulate the expression of a cell cycle checkpoint protein. Antisense nucleic acids (preferably 10 to 20 base pair oligonucleotides) capable of
20 specifically binding to expression control sequences or RNA are introduced into cells (*e.g.*, by a viral vector or colloidal dispersion system such as a liposome). The antisense nucleic acid binds to the target sequence in the cell and prevents transcription or translation of the target sequence. Phosphorothioate and methylphosphonate antisense oligonucleotides are specifically contemplated for therapeutic use by the
25 invention. The antisense oligonucleotides may be further modified by poly-L-lysine, transferrin polylysine, or cholesterol moieties at their 5' end.

The invention further provides methods to promote differentiation of a differentiation-inhibited cell comprising the step of contacting the cell with a compound that inhibits transcription of a polynucleotide encoding a cell cycle checkpoint protein.
30 Alternatively, the invention embraces methods for promoting differentiation of a differentiation-inhibited cell comprising the step of introducing into the cell a

-12-

polynucleotide encoding a mutated cell cycle checkpoint protein; said polynucleotide providing a dominant/negative phenotype in the cell. In both aspects, the preferred cell type is a tumor cell. A preferred tumor cell is selected from the group consisting of a rhabdomyosarcoma cell, a prostate tumor cell, a small cell lung carcinoma cell, a head squamous cell carcinoma cell, a neck squamous cell carcinoma cell, a cervical carcinoma cell, and a uterine cervix carcinoma cell.

Yet another aspect of the invention provides a method of identifying a compound that promotes differentiation of a differentiation-inhibited cell comprising the steps of (a) determining the expression levels of a differentiation marker protein in said differentiation-inhibited cell in the absence and presence of the compound; (b) comparing the expression levels of the differentiation marker determined in step (a); and (c) identifying as a promoter of differentiation a test compound that increases the expression level of the differentiation marker compared to the expression level in the absence of the test compound. In the preferred method, the expression levels of differentiation marker proteins is determined in the absence and presence of a putative modulating compound. An increase in the expression of the marker protein in the presence of the compound indicates that the compound promotes differentiation. Differentiation-inhibited cells can be prepared by transiently or stably transfecting cells with a polynucleotide encoding a cell cycle checkpoint protein. In a preferred embodiment, cells of the invention are stem cells, and more preferably are myoblast cell type. In myoblasts, marker proteins include myosin heavy chain (MHC), MyoD, myogenin, or MLC1/3, and cell cycle checkpoint proteins ATR and/or CHK1, as well as other proteins in the ATR cascade of proteins that effect cell cycle arrest. In hematopoietic stem cells, a marker protein is SCL; in neurogenic stem cells, MASH, neurogenin, and neuro D are exemplary markers; and in liver stem cells, marker proteins include NF- κ B, Stat3, and C/EBP. In another preferred embodiment, cells of the method are rhabdomyosarcoma cells. In still another aspect, the preferred cell cycle checkpoint protein is either ATR or CHK1.

As another aspect, the invention provides a method to identify a compound that effects reversion of a differentiated cell type to a non-differentiated state comprising the steps of (a) determining the expression levels of a differentiation marker protein in said differentiated cell in the absence and presence of the compound; (b) comparing the

-13-

expression levels of the differentiation marker determined in step (a); and (c) identifying as a promoter of reversion to a non-differentiated state a testy compound that decreases the expression level of the differentiation marker compared to the expression level in the absence of the test compound. Compounds identified by the method may act by increasing biological activity of a cell cycle checkpoint polypeptide or increasing transcription from a polynucleotide encoding a cell cycle checkpoint polypeptide. Preferably, the cell cycle checkpoint protein is ATR or CHK1.

In still another aspect, the invention provides a method for promoting differentiation in a differentiation-inhibited cell type comprising the step of contacting the cell with a compound that increases biological activity of MyoD, or a member of the MyoD-like family of proteins. In one aspect, the compound acts directly or indirectly with the protein to increase biological activity. In another aspect, the compound acts to increase transcription of polynucleotides encoding the protein. Preferred cells of the method are tumor cells; the preferred tumor cell is a rhabdomyosarcoma cell. The invention also includes methods to identify a compound that promotes differentiation of a differentiation-inhibited cell, said compound increasing biological activity of MyoD, said method comprising the steps of: a) determining the expression levels of a differentiation marker protein in said differentiation-inhibited cell in the absence and presence of the compound; b) comparing the expression levels of the differentiation marker determined in step (a); and c) identifying the compound that promotes differentiation on the basis of the ability of the compound to promote increased expression level of the differentiation marker in the presence of the compound and to increase biological activity of MyoD. The invention further embraces compounds identified by the method.

The expression levels of marker proteins can be determined by the methods well known in the art as well as those described herein. Exemplary methods include, but are not limited to, use of antibodies specific for proteins of interests, polynucleotide probes (DNA and RNA) which hybridize to the genes or mRNA encoding the differentiation marker proteins, or polynucleotides that bind to the encoded protein.

Cell cycle checkpoint protein inhibitors may be formulated in compositions comprising pharmaceutically acceptable carriers. Such compositions may additionally include chemotherapeutic agents. Dosage amounts indicated would be sufficient to result

-14-

in inhibition of checkpoint protein activity *in vivo*. Inhibitors may include, for example, polypeptides or peptides which specifically bind to the checkpoint protein or checkpoint protein-encoding nucleic acid, oligonucleotides which specifically bind to the checkpoint protein or checkpoint protein-encoding nucleic acid, and/or other non-peptide compounds (e.g., isolated or synthetic molecules). The action of the inhibitor may directly affect a specific checkpoint polypeptide activity or underlying polynucleotide expression, or may alternatively affect activity of a polypeptide, or expression from its underlying polynucleotide, downstream from a particular checkpoint polypeptide.

The pharmaceutical compositions optionally may include pharmaceutically acceptable (*i.e.*, sterile and non-toxic) liquid, semisolid, or solid diluents that serve as pharmaceutical vehicles, excipients, or media. Any diluent known in the art may be used. Exemplary diluents include, but are not limited to, polyoxyethylene sorbitan monolaurate, magnesium stearate, methyl- and propylhydroxybenzoate, talc, alginates, starches, lactose, sucrose, dextrose, sorbitol, mannitol, gum acacia, calcium phosphate, mineral oil, cocoa butter, and oil of theobroma.

The pharmaceutical compositions can be packaged in forms convenient for delivery. The compositions can be enclosed within a capsule, sachet, cachet, gelatin, paper, or other container. These delivery forms are preferred when compatible with entry of the immunogenic composition into the recipient organism and, particularly, when the immunogenic composition is being delivered in unit dose form. The dosage units can be packaged, *e.g.*, in tablets, capsules, suppositories or cachets.

The pharmaceutical compositions may be introduced into the subject to be treated by any conventional method including, *e.g.*, by intravenous, intradermal, intramuscular, intramammary, intraperitoneal, intrathecal, intraocular, retrobulbar, intrapulmonary (*e.g.*, aerosolized drug solutions) or subcutaneous injection (including depot administration for long term release); by oral, sublingual, nasal, anal, vaginal, or transdermal delivery; or by surgical implantation, *e.g.*, embedded under the splenic capsule, brain, or in the cornea. The treatment may consist of a single dose or a plurality of doses over a period of time.

When given parenterally, product compositions are generally injected in doses ranging from 1 $\mu\text{g/kg}$ to 100 mg/kg per day, preferably at doses ranging from

-15-

0.1 mg/kg to 50 mg/kg per day, and more preferably at doses ranging from 1 to 20 mg/kg/day. The product composition may be administered by an initial bolus followed by a continuous infusion to maintain therapeutic circulating levels of drug product.

Those of ordinary skill in the art will readily optimize effective dosages and administration regimens as determined by good medical practice and the clinical condition of the individual patient. The frequency of dosing will depend on the pharmacokinetic parameters of the agents and the route of administration. The optimal pharmaceutical formulation will be determined by one skilled in the art depending upon the route of administration and desired dosage. See for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042) pages 1435-1712, the disclosure of which is hereby incorporated by reference. Such formulations may influence the physical state, stability, rate of *in vivo* release, and rate of *in vivo* clearance of the administered agents. Depending on the route of administration, a suitable dose may be calculated according to body weight, body surface area or organ size. Further refinement of the calculations necessary to determine the appropriate dosage for treatment involving each of the above mentioned formulations is routinely made by those of ordinary skill in the art without undue experimentation, especially in light of the dosage information and assays disclosed herein, as well as the pharmacokinetic data observed in the human clinical trials discussed above. Appropriate dosages may be ascertained through use of established assays for determining blood levels dosages in conjunction with appropriate dose-response data. The final dosage regimen will be determined by the attending physician, considering various factors which modify the action of drugs, e.g. the drug's specific activity, the severity of the damage and the responsiveness of the patient, the age, condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. As studies are conducted, further information will emerge regarding the appropriate dosage levels and duration of treatment for various diseases and conditions.

It will be appreciated that the pharmaceutical compositions and treatment methods of the invention may be useful in the fields of human medicine and veterinary medicine. Thus, the subject to be treated may be a mammal, preferably human, or other animals. For veterinary purposes, subjects include, for example, farm animals including

-16-

cows, sheep, pigs, horses, and goats, companion animals such as dogs and cats; exotic and/or zoo animals; laboratory animals including mice, rats, rabbits, guinea pigs, and hamsters; and poultry such as chickens, turkeys, ducks and geese.

5 The invention also provides a method to determine differentiation potential of a cell comprising the step of measuring expression of a cell cycle checkpoint polypeptide in the cell, said cell with elevated expression of the cell cycle checkpoint polypeptide having a reduced potential to differentiate. The invention further includes methods to determine differentiation potential of a cell comprising the step of determining
10 copy number of a checkpoint gene in the cell, said cell with multiple copies of the cell cycle checkpoint gene having a lower potential to differentiate

Detailed Description of the Invention

The present invention is illustrated by the following examples. Example 1 describes identification of a dominant inhibitory locus in rhabdomyosarcomas. Example 2 reports on the isolation of isochromosome 3q from C2(Rh30)-2 Cells. In Example 3,
15 abnormalities in the mitotic spindle and loss of G1 checkpoint control in i(3q)-containing cells are described. Transfer of normal chromosome 3 into C2C12 cells is described in Example 4. Example 5 relates to forced expression of ATR that resulted in a phenocopy of the i(3q)-containing cells. Examples 6 and 7 discuss results which show that forced expression of CHK1 in p53⁺ and p53⁻ cells down-regulates expression of MyoD. Example
20 8 describes a screen for MyoD phosphorylation. Example 9 describes isolation of yeast and bacterial artificial chromosomes which encode ATR or CHK1. Example 10 demonstrates that a mutant ATR lacking kinase activity can restore cellular myogenesis.

Example 1

Identification of Dominant Inhibitory Loci in Rhabdomyosarcoma Cells

25 Expression of MyoD, a protein required for differentiation of myoblasts, is characteristic of rhabdomyosarcoma cells despite the fact that the sarcoma cells do not differentiate. The inability of the rhabdomyosarcoma MyoD to induce differentiation may therefore be due to the presence of some inhibitory factor or the absence of some factor required for MyoD-induced differentiation.

-17-

It has previously been reported that heterokaryon formation with 10T1/2 cells can be used to classify different rhabdomyosarcoma cell lines as having either a recessive or a dominant inhibitory phenotype with respect to muscle differentiation [Tapscott *et al.*, *Science*, 259:1450-1453 (1993)]. Three tumor cell lines, RD, Rh28, and RhJT, were identified which were capable of differentiating into muscle, and it was proposed that these cell lines have a recessive, non-differentiating phenotype that can be complemented by fusion with 10T1/2 cells. In contrast, one rhabdomyosarcoma cell line, Rh18, showed no differentiation following heterokaryon formation with 10T1/2 cells, indicating that the Rh18 cells contain a gene responsible for the dominant non-differentiating phenotype. It was later demonstrated that the Rh18 cells contain amplified MDM2 genes which were responsible for the dominant, non-differentiating phenotype [Fiddler *et al.*, *Mol. Cell Biol.* 16:5048-5057 (1996)].

Heterokaryon formation with a fifth rhabdomyosarcoma cell line, Rh30, resulted in an intermediate phenotype in which only 30% of heterokaryons were capable of differentiation. Two possible explanations were proposed for the intermediate phenotype of Rh30 cells. First, it is possible that Rh30 cells contain a dominant inhibitory locus which is present in only a subset of cells of the Rh30 cell population. The aneuploid nature of the cell line supports this possibility. Second, it is possible that the Rh30 cells have a recessive phenotype but a fraction of the cells in the Rh30 population have lost the capacity to express MyoD and myogenin. If this explanation were true, the MyoD and myogenin-negative cells would no longer be able to induce myogenesis when fused to 10T1/2 cells. This cell line was therefore chosen to examine the inability of MyoD to induce differentiation in rhabdomyosarcoma cells.

To distinguish between the possibilities of a dominant inhibitory locus and a recessive phenotype, the presence of dominant inhibitory loci was first examined by transferring chromosomes from Rh30 cells into the differentiation competent myoblast cell line, C2C12 (ATCC No. CRL-1772) as follows. All cell lines discussed were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 15% calf serum (Hyclone Laboratories) (growth medium). Rh30 cells were stably transfected with pRSVNEO by electroporation (300 volts, 960 μ FD in PBS) (BioRad), and approximately 2,000 clones were pooled and expanded for use as donors in microcell fusions. Rh30 cells

-18-

were micronucleated by adding 10.0 µg of colcemid per ml in DMEM plus 15% calf serum for 48 hours. The micronucleated cell populations were enucleated by centrifugation in the presence of 5 µg of cytochalasin B (Sigma) per ml and the isolated microcells were fused to C2C12 recipients as described previously [Fournier, *Proc. Natl. Acad. Sci., USA*, 78:6349-6353 (1981); Lugo *et al. Mol. Cell Biol.*, 7:2814-2820 (1987)]. Microcell hybrid clones were isolated using cloning cylinders after three to four weeks of selection in medium containing 500 µg of Geneticin or G418 (Gibco) per ml. The resulting microcell hybrids, named the C2(Rh30) series, were isolated, expanded, and assayed for the ability to differentiate.

Myogenic differentiation of the hybrid cells was induced by growing cells to confluence followed by incubation in DMEM with 2% horse serum (differentiation medium). Northern blot analysis was performed by preparing total cytoplasmic RNA as described [Favaloro *et al., Methods Enzymol.*, 65:718-749 (1980)]. Five micrograms total cytoplasmic RNA was used for Northern analysis on 1.5% agarose gels containing 6.7% formaldehyde. RNA was transferred to GeneScreen[®] (DuPont) by capillary transfer in 10X SSC (1X SSC is 150 mM NaCl, 15 mM sodium citrate). RNA was cross-linked to the membrane by exposure to UV followed by baking at 80°C for two to four hours. Blots were prehybridized for several hours at 42°C in hybridization buffer (50% formamide, 1% bovine serum albumin [fraction V], 1 mM EDTA, 0.5 M sodium phosphate [pH 7.2], 5% sodium dodecyl sulfate [SDS]). Hybridization was carried out for twenty-four hours at 42°C in fresh hybridization buffer containing 1×10^8 cpm of randomly primed [³²P]-labeled DNA probe comprising cDNA encoding MyoD, myogenin, MLC1/3, or CHO B [Fiddler *et al., Mol. Cell Biol.* 16:5048-5057 (1996)]. The filters were washed in 2X SSC/0.1% SDS for fifteen minutes at room temperature, 0.1X SSC/0.1% SDS for fifteen minutes at room temperature, and two changes of 0.1X SSC/0.1% SDS at 55°C for fifteen minutes each. The blots were stripped for reuse by boiling for two minutes in double-distilled water.

Two out of nine hybrids, C2(Rh30)-2 and C2(Rh30)-21, expressed reduced levels of MyoD and myogenin mRNA as well as low levels of myosin light chain 1/3 (MLC1/3) mRNA. A similar analysis on an additional 10 hybrids identified a third non-differentiating hybrid, designated C2(Rh30)-7. The observations were consistent with

-19-

the possibility that Rh30 cells contain a dominant inhibitory locus. While it is possible that the microcell hybrid clones C2(Rh30)-2, 7, and 21 represented non-differentiating variants of C2C12 cells, it is unlikely due to the low frequency ($\sim 10^{-6}$) of these variants in C2C12 populations [Peterson *et al.*, *Cell*, 62:493-502 (1990)], and due to the fact that, in control
5 fusions introducing chromosomes that do not inhibit myogenesis, non-differentiation hybrids were not observed [Fiddler *et al.*, *Mol. Cell Biol.* 16:5048-5057 (1996)].

Because microcell fusion using rhabdomyosarcomas as donors often results in transfer of more than one human chromosome [Fiddler *et al.*, *Mol. Cell Biol.* 16:5048-5057 (1996)], a second round of microcell fusions were performed in order to determine
10 if the neo^r insertions in each primary hybrid clone were linked to the inhibitory locus. C2(Rh30)-2, 7, and 21 were used as donors in microcell fusions with C2C12 cells as described above. The resulting secondary hybrids were assayed for muscle differentiation by visual inspection.

All of the secondary hybrids from C2(Rh30)-7 and C2(Rh30)-21 showed
15 extensive myotube formation indicating that the neo^r insertions in these two primary clones were not linked to a dominant inhibitory locus. Furthermore, C2(Rh30)-7 and C2(Rh30)-21 contained multiple human chromosomes.

In contrast, 24 out of 30 colonies generated from C2(Rh30)-2 failed to show significant myotube formation. Ten secondary hybrids, designated C2(R302)-1
20 through -10, were isolated, expanded, and analyzed for expression of muscle-specific markers. Northern blot hybridizations, using MyoD, myogenin, and MLC1/3 as probes [Fiddler *et al.*, *Mol. Cell Biol.* 16:5048-5057 (1996)] on RNA extracted from parental C2C12 cells and five of the secondary microcell hybrids indicated that four out of five hybrids (C2(R302)-3, -4, -5, and -6) express low levels of MyoD, myogenin, and MLC1/3
25 mRNA as compared to control C2C12 cells. Secondary C2(R302)-2 did not show reduced expression of MyoD, myogenin, and MLC1/3. The results indicated that C2(Rh30)-2 cells contained a dominant inhibitory locus and that the locus was linked to the neo^r marker.

-20-

Example 2
Identification of Isochromosome 3q from C2(Rh30)-2 Cells

To determine the human DNA content of C2(Rh30)-2, fluorescent *in situ* hybridization (FISH) with total human DNA as probe was performed as follows. DNA probes were nick-translated using standard protocols to incorporate biotin-11-dUTP or digoxigenin-dUTP. Slides of normal male metaphase chromosomal spreads were obtained from peripheral blood as previously described [Yunis and Chandler, *Prog. Clin. Pathol.*, 7:267-288 (1978)]. Hybridizations were carried out on slides at 37°C for sixteen hours with probes at a concentrations from 40-60 ng/μl. Signal detection was carried out as described [Trask and Pinkel, *Flow Cytometry, Methods in Cell Biology*, Vol 33, New York Academic Press (1990)]. Amplification of the biotinylated probe signal was carried out with alternating incubations of slides with anti-avidin (Vector) and FITC-Extravidin[®] (Sigma). Amplification of digoxigeninated probes was carried out with alternating incubations of slides with FITC-tagged sheep antibodies generated in rabbit and FITC-tagged rabbit antibodies generated in sheep (Boehringer Mannheim). Slides were stained with propidium iodide (0.3 μg/ml), coverslipped, and viewed under UV fluorescence with FITC filters (Zeiss). Metaphase spreads showing probe signals were photographed with Fuji color film (ASA 100) at ASA 400. Identification of chromosomal loci was determined by sequentially staining the same metaphase spreads with chromomycin A3/distamycin to produce fluorescent R-bands. R-banded metaphase spreads were then photographed with technical pan 2415 film (Kodak) at ASA 400. Because the C2C12 cells were of mouse origin and the human DNA probe derived from normal foreskin fibroblast cells did not hybridize to mouse DNA, the C2C12 chromosomes did not show any significant hybridization. However, hybridization to a single human chromosome was detected.

Analysis of G-labeled metaphase spreads [Yunis and Chandler, *Prog. Clin. Pathol.*, 7:267-288 (1978)] indicated that the human chromosome is an isochromosome 3q, i(3q), representing a reiteration of chromosome 3 bands q12-q26. FISH analysis indicated that i(3q) was present in the C2(R302) secondary hybrids that failed to differentiate and was absent from the hybrids that continued to differentiate.

In order to determine whether only chromosome 3 sequences were present on i(3q), FISH was performed with a chromosome 3-specific "paint" (Oncor,

-21-

Gaithersburg, MD) as probe. The results indicated that chromosome 3 sequences are present along the entire length of this chromosome and that i(3q) was derived from only chromosome 3 sequences. A similar analysis indicated that i(3q) was present in 50% of the parental Rh30 cells, indicating that a subset of the Rh30 cells contained a dominant inhibitory locus.

In order to characterize chromosome 3 DNA present on i(3q), C2(Rh30)-2 cells and secondary hybrids were screened for specific DNA sequences known to reside on human chromosome 3. The primary microcell hybrid C2(Rh30)-2 and the four hybrids, C2(R302)-3, 4, 5 and 6, shown to include the inhibitory locus retained markers from 3q12-26. One secondary hybrid, C2(R302)-2, that continued to differentiate, did not retain any of these markers. The other two non-muscle primary hybrids C2(Rh30)-7 and C2(Rh30)-21, were shown to contain the i(3q) as assayed by chromosome 3 "paint" and PCR analysis.

In order to determine whether the ATR gene was present in the i(3q) containing hybrids, the following assay was carried out. PCR analysis as described above was conducted on genomic DNA isolated from C2C12 cells and the i(3q) containing hybrid C2(Rh30)-2 using human ATR-specific primers, oDH23 (SEQ ID NO: 1) and oDH26 (SEQ ID NO: 2)

Primer oDH23 SEQ ID NO: 1

5' GACGCAGAATTCACCAGTCAAAGAATCAAAGAG 3'

Primer oDH26 SEQ ID NO: 2

5' TGGTTTCTGAGAACATTCCCTGA 3'

High molecular weight DNA (100 ng) was used as template in the presence of 67 mM Tris (pH 8.8), 16 mM (NH₄)₂SO₄, 10 mM 2-mercaptoethanol, 6.7 μM EDTA, 2.0 mM MgCl₂, 10% glycerol, 0.2 mM dNTPs, 0.2 pM primers, and 1.3 U *Taq* polymerase (Cetus). Following an initial four minute incubation at 96°C, samples were subjected to 35 cycles of 94°C for thirty seconds, 55°C for thirty seconds, and 72°C for thirty seconds. Samples were separated on 30% agarose gels and stained with ethidium bromide.

Results indicated that the human ATR gene was present in the C2(Rh30)-2 DNA but not in C2C12 DNA. To determine whether the human ATR gene was present

-22-

on both arms of the i(3q), therefore representing an increase in copy number, FISH analysis was performed as described above using ATR cDNA as probe. Results indicated the ATR gene was present on both arms of the i(3q).

Example 3
Abnormalities in the Mitotic Spindle and
Loss of G1 Checkpoint Control in i(3q)-Containing Cells

Abnormal Mitotic Spindles

During karyotypic analysis of the C2(Rh30) and C2(R302) hybrids, it was observed that the microcell hybrids containing the i(3q) contained many more mouse chromosomes than the parental C2C12 cells. Therefore, chromosomal counts on metaphase spreads from these microcell hybrids, as well as from C2C12 and the C2(3n) microcell hybrids containing normal human chromosome 3, were performed as previously described [Yunis and Chandler, *Prog. Clin. Pathol.*, 7:267-288 (1978)].

Results indicated that the parental C2C12 cells, as well as C2C12 microcell hybrids containing normal chromosome 3, displayed relatively stable tetraploid karyotypes with the majority of cells containing 76-85 chromosomes. In contrast, the microcell hybrids, C2(Rh30)-2, C2(Rh30)-21, C2(R302)-3, that retained i(3q) displayed aneuploid karyotypes with the majority of metaphase spreads containing greater than 156 chromosomes. Furthermore, metaphase spreads with greater than 300 chromosomes were observed in all three of the i(3q)-containing hybrids analyzed. These results indicated that introduction of the i(3q) into C2C12 cells caused the cells to become aneuploid, while transfer of normal chromosome 3 did not.

Because i(3q) caused a dramatic change in the chromosomal content of C2C12 cells, abnormalities in the mitotic spindle were examined by immunostaining with an antibody to β -tubulin. [Fukasawa *et al.*, *Science*, 271:1744-1747 (1996)]. C2C12 cells contained a typical bipolar array of antiparallel microtubules organized at the poles in 98% of mitotic figures. In contrast, 58% of the mitotic C2(Rh30)-2 cells contained more than two spindles organized by multiple spindle poles. Abnormal numbers of centrosomes were present in the C2(Rh30)-2 cells as assayed by immunostaining with an antibody to γ -tubulin (Sigma, St. Louis, MO.), while C2C12 cells contained one or two centrosomes per interphase cell. These results indicated that i(3q) caused abnormal

-23-

centrosome amplification. Centrosome abnormalities of this type have previously been reported in the absence of p53 expression [Fukasawa *et al.*, *Science*, 271:1744-1747 (1996)], suggesting that i(3q) inhibits normal p53 function.

Loss of G1 Checkpoint Control

5 Because the i(3q)-containing hybrids were found to have abnormal centrosome amplification similar to p53 null cells, and considering the role of p53 in cell cycle arrest at G1 [Donehower *et al.*, *Nature*, 356:215-221 (1992)], it was decided to examine whether i(3q) modified the host cell's DNA damage-induced cell cycle checkpoints using C2C12 cells and the C2(R302) hybrids following γ -irradiation.

10 Cells were irradiated in a ^{137}Cs γ -irradiator at 100 rads/min (1 rad=0.01Gy) for a total of 0 or 20 Gy and fed with fresh medium. After 17 hours, the cells were trypsinized, washed twice with 1% bovine serum albumin, and resuspended in 0.2 ml PBS. Cells were fixed by adding 5 ml of 70% ethanol at -20°C. Fixed cells were resuspended in 2 N HCl/0.5% Triton X-100 for thirty minutes at room temperature, and resuspended
15 in 0.1 M $\text{Na}_2\text{B}_4\text{O}_7 \cdot 10\text{H}_2\text{O}$ (pH 8.5) to neutralize the acid. Cells were stained with 5 $\mu\text{g}/\text{ml}$ propidium iodide (Sigma) and analyzed on a FACS flow cytometer (Becton Dickinson Immunocytometry Systems) at laser excitation of 488 nm.

 Results indicated that parental C2C12 cells retained a prominent G1 arrest mechanism following irradiation but that the hybrid C2(R302)-3, which contained the
20 i(3q), contained two distinct abnormal features. First, the DNA content of the control C2(R302)-3 cells (which were not irradiated) was approximately twice that of the parental C2C12 cells. This observation was consistent with the previous observation that these cells contain approximately twice the number of chromosomes as the parental C2C12 cells. Second, the C2(R302)-3 cells showed a dramatic decrease in the G1 population
25 following γ -irradiation, indicating a lack of a functional G1 checkpoint similar to the phenotype in p53 null cells [Donehower *et al.*, *Nature*, 356:215-221 (1992)]. The similarity suggested that i(3q) inhibited normal p53 function following DNA damage.

Example 4

Transfer of Normal Chromosome 3 Does Not Inhibit Myogenesis

-24-

In view of the identification of an inhibitory locus on i(3q) which is derived from chromosome 3 DNA, it was decided to examine whether normal human chromosome 3 contains a similar inhibitory locus.

5 Normal chromosome 3 was introduced into C2C12 cells by microcell fusion as described in Example 1 with GM11713 cells (Coriell Institute for Medical Research, Camden, NJ), an A9 cell line retaining a single copy of normal human chromosome 3 into which a neo^r gene has been inserted. Fused cells were identified by selecting for transfer of the chromosome 3 in G418. Resulting hybrid clones, designated the C2(3n) series, were isolated, expanded, and assayed (i) for the ability to differentiate
10 into muscle by visual inspection for the presence of myotubes, and (ii) by Northern blot hybridizations using MyoD, myogenin, and MLC1/3 cDNAs as probes as described in Example 1.

Results from six clones examined indicated that, in addition to myotube formation, all of the C2(3n) hybrids expressed high levels of MyoD, myogenin, and
15 MLC1/3 mRNA. These observations indicate that transfer of normal human chromosome 3 into C2C12 cells did not inhibit muscle cell differentiation, and suggested that the phenotypic alterations observed in the i(3q) hybrids was due to genetic alterations that occurred in the generation of the abnormal rhabdomyosarcoma chromosome.

-25-

Example 5**Forced Expression of ATR Results in a Phenocopy of Isochromosome i(3q)**

The results described in the above examples indicated that a genetic alteration present on the i(3q) inhibits muscle differentiation and causes numerous cell cycle abnormalities when introduced into C2C12 cells. The results, however, did not permit identification of genes which participate in the inhibitory mechanism. Several hypotheses have been proposed to explain how MyoD, as well as others in the family of proteins, are kept in check during proliferation: 1) inhibition of the MyoD family members by interaction with the Id family of negative HLH factors [Benezra *et al.*, *Cell*, 61:49-59 (1990)], 2) inhibitory phosphorylation of the MyoD family members by protein kinase C [Li *et al.*, *Cell*, 71:1181-1194 (1992); Hardy *et al.*, *Mol. Cell Biol.*, 13:5943-5956 (1993)], and 3) inhibition by cyclin-D dependent kinases [Rao *et al.*, *Mol. Cell Biol.* 14:5259-5267 (1994b); Skapek *et al.*, *Science*, 267:1022-1024 (1995)]. It is well known in the art to characterize genes by purely genetic approaches. Thus, it should be possible to analyze candidate genes that map to the identified chromosomal locus, and oncogenes (e.g. ECT2, EVI1, FIM3, and BCL6), negative HLH factors (Hairy), and cell cycle related proteins (ATR and CDCL1) that map to 3q as candidate genes were considered for the muscle inhibitory locus. In view of the numerous cell cycle alterations observed in the i(3q) hybrids, one gene in particular was considered to be a likely candidate.

The ATR gene, which is related to ATM (ataxia telangiectasia mutated [Savitsky *et al.*, *Science*, 268:1749-1753 (1995)] and is the human homolog of the *Saccharomyces cerevisiae* MEC1 and *Schizosaccharomyces pombe* Rad3 genes, has been mapped to 3q22-24 [Cimprich *et al.*, *Proc. Natl. Acad. Sci. USA*, 93:2850-2855 (1996); Keegan *et al.*, *Genes Dev.*, 10:2423-2437 (1996)]. While there have not yet been any reports of mammalian phenotypes associated with ATR, mutations in the ATM gene lead to pleiotropic defects in cell cycle regulation following DNA damage, including loss of the G1/S and G2/M checkpoints [Hawley and Friend, *Genes Dev.*, 10:2383-2388 (1996); Hoekstra, *Curr. Opin. Genet. Dev.*, 7:170-175 (1997)]. In addition, mutations in either the *S. cerevisiae* MEC1 or the *S. pombe* RAD3 gene leads to similar defects in cell cycle checkpoint control [reviewed in Carr, A.M., *Curr. Opin. Genet. Dev.*, 7:93-98 (1997)].

To determine whether ATR is involved in the non-differentiating phenotype and/or cell cycle abnormalities of the i(3q) containing hybrids, C2C12 cells

-26-

were stably transfected with an expression vector encoding ATR as a fusion protein with a six histidine tag. Construction of the vector was carried out as follows..

PCR was carried out using primers MCCS6his (SEQ ID NO: 3) and ATR1R (SEQ ID NO: 4) that would incorporate sequences encoding the histidine tag adjacent sequences encoding the amino-terminus of ATR. Amplification conditions included 100 ng PstA 12 ATR template DNA; 1X PCR buffer (Perkin Elmer, Cetus), 1.5 mM MgCl₂; 200 μM each dATP, dGTP, dCTP, and dTTP; 10 ng/μl each primer; 1 unit *Taq* polymerase (Perkin Elmer, Cetus).

MCCS6his (SEQ ID NO: 3)
10 5'-CGGGATCCAGCATGCATCACCATCACCATCACATGGGGGAACATGGGC-3'

ATR1R (SEQ ID NO: 4)
5'-CATGACCACTGGCCATTCCACACG-3'

The reaction was first incubated at 94°C for thirty seconds, followed by 25 cycles of 94°C for thirty seconds, 60°C for thirty seconds, and 72°C for thirty seconds. The approximately 800 bp amplification product was digested with *Bam*HI and *Msc*I and ligated to two other fragments: a 10 kb fragment from pcDNAATR digested with *Bam*HI and *Bst*XI and an approximately 3 kb *Msc*I to *Bst*XI fragment containing the remainder of the ATR coding sequence. The resulting plasmid encoding a six-histidine tagged full length ATR molecule was designated pcDNA6his ATR.

20 C2C12 cells were transfected with pcDNA6hiSATR, grown in media containing G418 for three weeks to allow colonies to form, induced to differentiate in low serum media, and scored for muscle differentiation by immunostaining with a myosin heavy chain (MHC) antibody [Bader and Fischman, *J. Cell Biol.*, 95:763-770 (1982)].

Control transfections, using empty expression vector, resulted in 100% of colonies (150/150) showing extensive cell fusion and positive staining with the MHC antibody. In contrast, 25% (50/200) of the colonies from the ATR transfected cells showed a dramatic reduction in MHC immunoreactivity.

To confirm the non-differentiating nature of these ATR transfected cells, and to test for cell cycle alterations, several non-fusing colonies, designated the C2ATR series clones, were isolated and expanded. Northern blot hybridizations to determine

-27-

expression of MyoD, myogenin and MLC1/3 were carried out as described in Example 1 on RNA from two ATR transfected clones.

Two clones, C2ATR-1 and C2ATR-5, were found to express reduced levels of MyoD, myogenin, and MLC1/3 mRNA as compared to parental C2C12 cells. Thus, the C2C12 cells transfected with the ATR expression vector have a phenotype similar to the i(3q) hybrids with respect to muscle differentiation. Chromosome counts on the two clones indicated the two contained aneuploid karyotypes similar to the i(3q) containing hybrids. Chromosome counts on C2C12 clones transfected with empty expression vector (C2cDNA1 and 2), showed that all clones retained a stable tetraploid karyotype. Immunostaining C2ATR-1 and C2ATR-5 with the β and γ tubulin antibodies showed centrosome amplification leading to supernumerary spindles.

Forced expression of ATR therefore resulted in a phenocopy of the i(3q) containing hybrids, and that duplication of ATR by isochromosome formation caused loss of myogenic differentiation, abnormal centrosome amplification, and aneuploidy in the rhabdomyosarcoma cell line Rh30.

In order to determine if the i(3q) phenotype arose from rearrangement of the ATR encoding gene, Southern analysis was carried out as follows. High molecular weight DNA (10 μ g) was digested to completion with *Hind*III and separated on 0.8% agarose gels in 0.04 M Tris acetate/2 mM EDTA. The DNA was transferred to GeneScreen[®] (Dupont) membranes in 10X SSC (1X SSC is 150 mM NaCl, 15 mM Na-citrate), and UV crosslinked. Probes containing Alu sequences were processed and hybridized as described by Budowle and Baechtel, *Appl. Theor. Electrophor. 1*:181-187 (1990), to minimize background from repetitive sequences. The blots were stripped for reanalysis by incubation in 0.2N NaOH for thirty minutes.

Based upon the observations previously described in this Example, it was proposed that the phenotypic consequences result from overexpression of ATR as a result of chromosome duplication.

-28-

Example 6
Forced Expression of ATR or CHK1 in C2C12 and NIH3T3
Cells Results in Down-Regulation of MyoD

To test whether forced expression of ATR affects MyoD function, transient transfection assays were performed in NIH3T3 (ATCC No. CRL6361) cells co-transfected with MyoD and ATR. Cells were transiently co-transfected by the Lipofectamine (GibcoBRL) method with an expression plasmid encoding ATR and a second plasmid encoding a reporter gene under control of regulatory sequences recognized and acted upon by MyoD. Approximately 3×10^5 cells were plated one day prior to transfection into 60 mm tissue culture plates. Transfection mixtures were comprised of 6 μ g total DNA, with 0.5 to 1.0 μ g being the reporter construct encoding chloramphenicol acetyltransferase (CAT). The lipid-DNA mixtures were added to the cells and brought to a final volume of 2 milliliters with serum-free DMEM. The transfection mixture was allowed to sit on the cells for six hours after which the transfection solution was removed by aspiration. DMEM containing 15% calf serum was added to the cells, and the cells were harvested after approximately 48 hours.

CAT activity was measured using a phase extraction procedure. In brief, 48 hours after transfection, cell extracts were generated by freeze-thawing cell pellets in 100 μ l 0.25 M Tris (pH 7.5). Following treatment at 65°C for 15 min to inactivate endogenous acetylases, 30 μ l of extract was assayed with 0.2 mCi of [3 H] chloramphenicol (Dupont-New England Nuclear) and 250 nM butyryl-CoA (Sigma), in a total volume of 100 μ l. The reaction was allowed to proceed for 2 to 12 hours at 37°C and stopped by mixing with 200 μ l TMPD-Xylene (2:1) (Sigma). One hundred thirty microliters of the upper phase was removed and added to scintillation cocktail to be counted.

Co-transfecting increasing amounts of ATR expression vector inhibited the ability of MyoD to transactivate the MyoD dependent reporter construct 4RtkCAT, but had little affect on the ability of gal. VP16 to transactivate the GAL dependent reporter construct gal.CAT. These results suggested that ATR inhibited MyoD dependent transactivation.

Because CHK1 activity in *S. pombe* is dependent upon the ATR yeast homolog, Rad3, it was next tested whether forced expression of human CHK1 would

-29-

result in the same phenotypes as the i(3q) and ATR. Initially, C2C12 (ATCC No. CRL 1772) cells were stably transfected with a pCINEO-based (Invitrogen, San Diego) CHK1 expression vector using a BIORAD electroporator. Stable transfectants were selected in media containing G418, grown for three weeks to allow colonies to form, induced to differentiate in low serum media, and scored for muscle differentiation by immunostaining with a myosin heavy chain (MHC) antibody [Bader and Fischman, *J. Cell Biol.*, 95:763-770 (1982)].

Control transfections, using empty expression vector (pCINEO), resulted in 100% (200/200) of colonies showing extensive cell fusion and positive staining with the MHC antibody. In contrast, 31% (62/200) of the colonies from the CHK1 transfection showed a dramatic reduction in MHC immunoreactivity.

To determine whether the CHK1-transfected clones contain cell-cycle abnormalities similar to the i(3q) hybrids, chromosome counts on two ATR stable lines, C2CHK-3 and C2CHK-4 were conducted. Similar to the i(3q) containing hybrids, these two clones contain aneuploid karyotypes. Immunostaining C2CHK-3 with the γ and β tubulin antibodies showed centrosome amplification leading to supernumerary spindles.

To examine whether forced expression of CHK1 also affects MyoD function, transient transfection assays were performed in NIH3T3 (ATCC No. CRL6361) cells co-transfected with MyoD and CHK1. Cells were transiently co-transfected by the Lipofectamine (GibcoBRL) method. Approximately 3×10^5 cells were plated one day prior to transfection into 60 mm tissue culture plates. Transfection mixtures were comprised of a total DNA content of 6 μ g with 0.5 to 1.0 μ g being CAT reporter construct. The lipid-DNA mixtures were added to the cells and brought to a final volume of two milliliters with serum-free DMEM. The transfection mixture was allowed to sit on the cells for six hours after which the transfection solution was removed by aspiration. DMEM containing 15% calf serum was added to the cells, and the cells harvested after approximately 48 hours. CAT activity was measured using the phase extraction procedure described above.

Results indicated that co-transfecting increasing amounts of CHK1 expression vector inhibited the ability of MyoD to transactivate the MyoD dependent reporter construct 4RtkCAT, but had little effect on the ability of gal. VP16 to

-30-

transactivate the GAL dependent reporter construct gal.CAT. Like ATR, therefore, forced expression of CHK1 inhibits MyoD dependent transactivation.

Example 7

Forced Expression in A5 Cells Results in Down-Regulation of MyoD

5 Because the phenotype of cells containing the i(3q), as well as cells transfected with ATR or CHK1, display a phenotype very similar to p53 null cells [Donehower *et al.*, *Nature* 365: 215-221 (1992); Fukasawa *et al.*, *Science* 271:1744-1747 (1996)], it was tested whether the inhibition of MyoD activity by either ATR or CHK1 was dependent on p53 gene function.

10 A transient transfection assay in A5 cells, p53^{-/-} mouse embryo fibroblasts (MEFs) [Donehower, *et al. supra*], was employed wherein cells were transiently co-transfected by the Lipofectamine (GibcoBRL) method. Approximately 3×10^5 cells were plated one day prior to transfection into 60 mm tissue culture plates. Transfection mixtures comprised 6 μ g total DNA with 0.5 to 1.0 μ g being reporter construct. The
15 lipid-DNA mixtures were added to the cells and brought to a final volume of 2 milliliters with serum-free DMEM. The transfection mixture was allowed to sit on the cells for six hours after which the transfection solution was removed by aspiration. DMEM containing 15% calf serum was added to the cells, and the cells harvested after approximately 48 hours. CAT activity was measured using the phase extraction procedure described above.

20 Co-transfecting increasing amounts of CHK1 expression vector inhibited the ability of MyoD to transactivate the MyoD dependent reporter construct 4RtkCAT in the p53 null cells. In contrast, co-transfecting increasing amounts of ATR had no affect on the ability of MyoD to transactivate 4RtkCAT. These results indicated that inhibition of MyoD activity by ATR is p53 dependent but that CHK1 inhibition is not. The results
25 also suggest that in the ATR cell cycle checkpoint pathway, p53 is downstream from ATR and upstream to CHK1.

Example 8

MyoD Phosphorylation Assay

30 In order to screen for chemical modulators of ATR, a MyoD-based assay was developed as follows.

-31-

ATR was captured on a 96 well plate previously coated first with goat anti-mouse antibodies (Pierce) and secondly with anti-ATR antibody 224C. A hybridoma which secretes antibody 224C was deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, MD 20852 on November 7, 1996 and assigned ATCC Accession Nos. HB 12233. The 224C antibody was added to the plate at a concentration of 2 mg/ml in BT blocking buffer and incubated for at least 30 hours at 4°C. The wells were washed with TBS containing 0.05% Tween[®] 20 and mouse testes extract (prepared as described in Example 6 of WO 97/18323 published May 22, 1997 from International Application No. PCT/US96/19337, incorporated herein by reference) was added. Incubation was continued for an additional 20 hours at 4°C. The wells were washed again as before and a kinase reaction was carried out as follows.

A kinase reaction mixture, containing kinase buffer (as described in Example 6 of WO 97/18323), 10 µg ATP, 5 µCi ³²P-γATP, and a peptide substrate, designated IDH22 (SEQ ID NO: 8) and derived from the MyoD protein, was added to each well and incubation carried out at room temperature for 40 minutes. The selection of this peptide substrate is described below.

IDH22

SEQ ID NO: 8

NH₂- Leu-Lys-Arg-Cys-Thr-Ser-Ser-Asn-Pro-Asn-Gln-Arg-Leu-Pro-Lys-COOH

The supernatant, containing the ³²P-labeled peptide was transferred to P81 phosphocellulose paper, the paper was washed three times with 100 mM phosphoric acid (to remove unincorporated label) and once with ethanol, and Cerenkov radiation (in counts per minute, cpm) was counted in a scintillation counter.

Chemical modulators are added to the reaction mixture before the kinase reaction mixture and the effect of the modulator on ATR activity is determined by a change in cpm.

MyoD is a 319 amino acid transcription factor that is often phosphorylated in cells. As described in Example 6 (of WO 97/18323), it has been determined that ATR phosphorylates MyoD in *in vitro* kinase assays and the target serine residue in myoD has been identified using a MyoD deletion peptide, B-HLH containing amino acids 102

-32-

through 165. In view of these observations, two peptides were designed to map more precisely the site of phosphorylation. The first peptide IDH21 (SEQ ID NO: 9) included amino acids 119 through 130 and the second, IDH22. (SEQ ID NO: 8) comprised amino acid residues 132 through 146. Utilizing the kinase assay described above, it was observed that ATR phosphorylated IDH22 but not IDH21.

IDH21
NH₂-Arg-Arg-Arg-Leu-Ser-Lys-Val-Asn-Glu-Ala-Phe-Glu-COOH

SEQ ID NO: 9

Example 9

Isolation of ATR Genomic Yeast Artificial Chromosomes and Genomic Bacterial Artificial Chromosomes and CHK1 Genomic Chromosome

Pooled DNA samples from CEPH human yeast artificial chromosome (YAC) library and PRC1-11 bacterial artificial chromosome (BAC) library (both from Research Genetics, Huntsville AL) were screened to identify clones containing ATR or CHK1 coding regions. For both YAC and BAC cloning, pooled samples were amplified by PCR, and positive samples were used to identify subpools for second round amplification. Positive signals in the second amplification were used to identify master plates of individual YAC and BAC clones and a third amplification was carried out to identify individual clones. Conditions for the amplification reactions were as follows.

To identify YAC and BAC clones, PCR was carried out under conditions including 25 ng genomic DNA template, 80 pM primers (as set out below), 200 μ M each nucleotide triphosphate, and 2.5 U AmpliTaq[®] DNA polymerase (Perkin Elmer) in a reaction buffer containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, and 1 mM MgCl₂. Reactions included an initial incubation at 93°C for four minutes, followed by 30 cycles of 93°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds, followed by a final incubation at 72°C for seven minutes. Amplification products were detected using agarose gel electrophoresis. In order to identify ATR genomic clones, primers oATR23 (SEQ ID NO: 1) and oATR26 (SEQ ID NO: 2) were employed. To identify CHK1 genomic clones, primer pair MH171 (SEQ ID NO: 5) and MH174 (SEQ ID NO: 7) were used to amplify a 270 base pair CHK1 fragment, and pair MH173 (SEQ ID NO: 6) and MH174 (SEQ ID NO: 7) were used to amplify a 230 base pair fragment.

-33-

Primer MH171 SEQ ID NO: 5
CTCGGTGAATATAGTGCTGC

Primer MH173 SEQ ID NO: 6
GAGAAGATTATCCTGTCCTG

5 Primer MH174 SEQ ID NO: 7
 CTTGGTTTCCACCAGATGAG

For ATR, genomic YAC clones 941G12, 935A8, 895B8, 941B12, 967H4, and 906F5 were identified. A single genomic BAC encoding ATR, BAC279N71, was identified. For CHK1, genomic YACs 883H1 and 975F11 were identified. All YAC and
10 BAC clones are commercially available from Research Genetics (Huntsville, AL).

Example 10
Kinase Inactive ATR Restores Myogenesis in C2C12 Cells Containing i(3q)

Two recent studies have shown that overexpression of protein kinase mutants of ATR interfere with normal cell cycle checkpoint control, presumably by
15 interfering with endogenous wild type ATR activity [Cliby, *et al.*, *EMBO J.* 17:159-169 (1998); Wright, *et al.*, *Proc. Natl. Acad. Sci. (USA)* 95:7445-7450 (1998), Tibbetts, *et al.*, *Genes Dev.* 13:152-157 (1999)]. Because wild type ATR has been shown to block muscle differentiation [Smith, *Nature Genetics* 19:39-47 (1998)], it was next examined whether a kinase inactive ATR (ATR-kd) could restore muscle differentiation when
20 expressed in the i(3q) containing hybrid C2(R302)-5.

To test the hypothesis, an expression plasmid was constructed in parental plasmid pcDNA3 (Invitrogen) comprising DNA encoding a mutant ATR lacking kinase activity. Like many kinases, the ATR catalytic domain contains one or more amino acids that are crucial for enzyme activity. In generating the ATR mutant, an aspartate at
25 position 2494 was replaced with a glutamate by site directed mutagenesis using the mutagenic oligonucleotide shown in SEQ ID NO: 10.

GCGTACATGTAGAATTCAATTGTCTTTTCA

SEQ ID NO: 10

The resulting plasmid was designated ATR-kd.

-34-

Following transfection and selection, colonies were induced to differentiate, and scored for muscle differentiation by immunostaining with a MHC antibody [Bader, *et al.*, *supra*]. Control transfections, using empty expression vector, resulted in no colonies (0/150) showing extensive cell fusion and MHC immunoreactivity, with an occasional cell staining positive with the MHC antibody. In contrast, colonies from the ATR-kd transfection showed a significant increase in MHC immunoreactivity with 17% of the colonies (26/150) showing myotube formation and positive staining with the MHC antibody. This result indicated that forced expression of ATR-kd can restore myogenesis in the presence of i(3q), and that constitutive overexpression of ATR kinase activity is responsible for the phenotypic alterations in the i(3q)-containing cells.

While the present invention has been described in terms of specific embodiments, it is understood that variations and modifications will occur to those skilled in the art. Accordingly, only such limitations as appear in the appended claims should be placed on the invention.

-35-

What is Claimed is:

1. A method for inhibiting differentiation of a cell comprising the step of transforming or transfecting said cell with a polynucleotide encoding a cell cycle checkpoint protein.
2. The method of claim 1 wherein the cell is stably transformed or transfected.
3. The method of claim 1 wherein the cell is transiently transformed or transfected.
4. The method of any one of claims 1, 2, and 3 wherein the cell is a stem cell.
5. The method of claim 4 wherein the cell is selected from the group consisting of a myoblast, a hematopoietic stem cell, a neurogenic stem cell, a liver stem cell, and a germ cell.
6. The method of claim 1 or 5 wherein the cell cycle checkpoint protein is ATR.
7. The method of claim 1 or 5 wherein said cell cycle checkpoint protein is CHK1.

-36-

8. A method to identify a compound that inhibits differentiation of a cell, said compound increasing transcription of a polynucleotide encoding a cell cycle checkpoint protein, said method comprising the steps of:

- a) determining the degree of differentiation of a cell line in the presence and absence of a test compound;
- b) comparing the degrees of differentiation in step a); and
- c) identifying as an inhibitor of differentiation a test compound that reduces the degree of differentiation and increases the level of transcription of the polynucleotide encoding the cell cycle checkpoint protein compared to the degree of differentiation and level of transcription in the absence of the test compound.

9. A compound identified by the method of claim 8.

10. A method for inhibiting differentiation of a cell comprising the step of contacting the cell with a compound that increases transcription of a polynucleotide encoding a cell cycle checkpoint protein.

11. The method of claim 10 wherein the cell is a stem cell.

12. The method of claim 11 wherein the cell is selected from the group consisting of a myoblast, a hematopoietic stem cell, a neurogenic stem cell, a liver stem cell and a germ cell.

13. The method of claim 10 wherein the cell cycle checkpoint protein is ATR.

14. The method of claim 10 wherein said cell cycle checkpoint protein is CHK1.

-37-

15. A method to identify a compound that inhibits differentiation of a cell, said compound increasing biological activity of a cell cycle checkpoint protein, said method comprising the steps of:

- a) determining the degree of differentiation of a cell line in the presence and absence of a test compound;
- b) comparing the degrees of differentiation in step a); and
- c) identifying as an inhibitor of differentiation a test compound that reduces the degree of differentiation and increases the biological activity of the cell cycle checkpoint protein compared to the degree of differentiation and biological activity in the absence of the test compound.

16. A compound identified by the method of claim 15.

17. A method for inhibiting differentiation of a cell comprising the step of contacting the cell with a compound that increases biological activity of a cell cycle checkpoint protein.

18. The method of claim 17 wherein the cell is a stem cell.

19. The method of claim 18 wherein the cell is selected from the group consisting of a myoblast, a hematopoietic stem cell, a neurogenic stem cell, a liver stem cell and a germ cell.

20. The method of claim 17 wherein the cell cycle checkpoint protein is ATR.

21. The method of claim 17 wherein said cell cycle checkpoint protein is CHK1.

-38-

22. A method for identifying a compound that promotes differentiation of a differentiation-inhibited cell, said compound inhibiting biological activity of a cell cycle checkpoint protein; said method comprising the steps of:

- a) determining the expression levels of a differentiation marker protein in said differentiation-inhibited cell in the absence and presence of the compound;
- b) comparing the expression levels of the differentiation marker determined in step a); and
- c) identifying as a promoter of differentiation a test compound that increases the expression level of the differentiation marker and inhibits biological activity of the cell cycle checkpoint protein compared to the level of differentiation and biological activity in the absence of the test compound.

23. A method for identifying a compound that promotes differentiation of a differentiation-inhibited cell, said compound inhibiting transcription of a polynucleotide encoding a cell cycle checkpoint protein; said method comprising the steps of:

- a) determining the expression levels of a differentiation marker protein in said differentiation-inhibited cell in the absence and presence of the compound;
- b) comparing the expression levels of the differentiation marker determined in step a); and
- c) identifying as a promoter of differentiation a test compound that increases the expression level of the differentiation marker and inhibits transcription of the polynucleotide encoding the cell cycle checkpoint protein compared to the expression level and transcription in the absence of the test compound.

-39-

24. A compound identified by the method of claim 22 or 23.
25. The method of claim 22 or 23 wherein the differentiation marker protein is selected from the group consisting of the myosin heavy chain, MyoD, myogenin and MLC1/3.
26. The method of claim 22 or 23 wherein the differentiation marker protein is SCL.
27. The method of claim 22 or 23 wherein the differentiation marker protein is selected from the group consisting of MASH, neurogenin, and neuro D.
28. The method of claim 22 or 23 wherein the differentiation marker protein is selected from the group consisting of NF- κ B, Stat3.
29. The method of claim 22 or 23 wherein said cell cycle checkpoint protein is ATR.
30. The method of claim 22 or 23 wherein said cell cycle checkpoint protein is CHK1.
31. A method for promoting differentiation of a differentiation-inhibited cell comprising the step of contacting the cell with a compound that inhibits biological activity of a cell cycle checkpoint protein.
32. A method for promoting differentiation of a differentiation-inhibited cell comprising the step of contacting the cell with a compound that inhibits transcription of a polynucleotide encoding a cell cycle checkpoint protein.
33. A method for promoting differentiation of a differentiation-inhibited cell comprising the step of introducing into the cell a polynucleotide encoding a mutated

-40-

cell cycle checkpoint protein; said polynucleotide providing a dominant/negative phenotype in the cell.

34. The method of claim 31, 32, or 33 wherein the differentiation-inhibited cell is a tumor cell.

35. The method of claim 36 wherein said differentiation-inhibited cell is selected from the group consisting of a rhabdomyosarcoma cell, a prostate tumor cell, a small cell lung carcinoma cell, a head squamous cell carcinoma cell, a neck squamous cell carcinoma cell, a cervical carcinoma cell, and a uterine cervix carcinoma cell.

36. A method to identify a compound that promotes differentiation of a differentiation-inhibited cell, said compound increasing biological activity of MyoD, said method comprising the steps of

- a) determining the expression levels of a differentiation marker protein in said differentiation-inhibited cell in the absence and presence of the compound;
- b) comparing the expression levels of the differentiation marker determined in step a); and
- c) identifying as a promoter of differentiation a test compound that increases the expression level of the differentiation marker and increases the biological activity of MyoD compared to the expression level and biological activity in the absence of the test compound.

37. A compound identified by the method of claim 36.

38. A method for promoting differentiation of a differentiation-inhibited cell comprising the step of contacting the cell with a compound that increases the biological activity of MyoD.

-41-

39. The method of claim 38 wherein the differentiation-inhibited cell is a tumor cell.

40. The method of claim 38 wherein the tumor cell is a rhabdomyosarcoma cell.

41. A method for promoting differentiation of a differentiation-inhibited cell comprising the step of modifying an endogenous gene sequence encoding a cell cycle checkpoint protein such that the cell expresses the cell cycle checkpoint protein at a reduced level.

42. The method according to claim 41 wherein the endogenous gene sequence is modified in the protein coding region.

43. The method according to claims 41 wherein the endogenous gene sequence is modified in a transcriptional regulatory region.

44. A method for promoting differentiation of a differentiation-inhibited cell comprising the step of introducing into a cell a first polynucleotide encoding an anti-sense polynucleotide that hybridizes to a second polynucleotide encoding a cell cycle checkpoint protein.

45. A method for reverting differentiation of a differentiated cell comprising the step of contacting the differentiated cell with a compound that increases biological activity of a cell cycle checkpoint protein.

46. A method for reverting differentiation of a differentiated cell comprising the step of contacting the differentiated cell with a compound that increases transcription of a polynucleotide encoding a cell cycle checkpoint protein.

-42-

47. The method of claim 45 or 46 wherein the cell cycle checkpoint protein is selected from the group consisting of ATR and CHK1.

48. A method for reverting differentiation of a muscle cell comprising the step of contacting the muscle cell with a compound that inhibits biological activity of MyoD.

49. A method to determine differentiation potential of a cell comprising the step of measuring expression of a cell cycle checkpoint polypeptide in the cell, said cell with elevated expression of the cell cycle checkpoint polypeptide having a reduced potential to differentiate.

50. A method to determine differentiation potential of a cell comprising the step of determining copy number of a checkpoint gene in the cell, said cell with multiple copies of the cell cycle checkpoint gene having a lower potential to differentiate.

- 1 -

SEQUENCE LISTING

<110> Hoekstra, Merl
Thayer, Mathew

<120> Materials and Methods for Modulating Differentiation

<130> 27866/35599

<140>

<141>

<150> 09/067,284

<151> 1998-04-27

<160> 10

<170> PatentIn Ver. 2.0

<210> 1

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 1

gacgcagaat tcaccagtca aagaatcaaa gag

33

<210> 2

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 2

-2-

tggtttctga gaacattccc tga

23

<210> 3

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 3

cgggatccag catgcatcac catcaccatc acatggggga acatgggc

48

<210> 4

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 4

catgaccact ggccattcca cacg

24

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 5

ctcgggtgaat atagtgtctgc

20

<210> 6

<211> 20

- 3 -

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 6

gagaagatta tcctgtcctg

20

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 7

cttggtttcc accagatgag

20

<210> 8

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide substrate

<400> 8

Leu	Lys	Arg	Cys	Thr	Ser	Ser	Asn	Pro	Asn	Gln	Arg	Leu	Pro	Lys
1					5				10				15	

<210> 9

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

- 4 -

<223> Description of Artificial Sequence: peptide substrate

<400> 9

Arg Arg Arg Leu Ser Lys Val Asn Glu Ala Phe Glu

1

5

10

<210> 10

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: mutagenesis
oligonucleotide

<400> 10

gcgtacatgt agaattcaat tgtctttttca

30



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 5/10, 15/85, 9/12, 15/54, 15/12, C07K 14/47, G01N 33/50	A3	(11) International Publication Number: WO 99/55844 (43) International Publication Date: 4 November 1999 (04.11.99)
(21) International Application Number: PCT/US99/09102 (22) International Filing Date: 27 April 1999 (27.04.99) (30) Priority Data: 09/067,284 27 April 1998 (27.04.98) US (71) Applicants: ICOS CORPORATION [US/US]; 22021 20th Avenue, S.E., Bothell, WA 98021 (US). OREGON HEALTH SCIENCE UNIVERSITY [US/US]; 3181 Southwest Sam Jackson Park Road, Portland, OR 97201 (US). (72) Inventors: HOEKSTRA, Merl, F.; 10321 216th Street, S.E., Snohomish, WA 98290 (US). THAYER, Matthew, J.; 2954 N.W. Xavier Street, Portland, OR 97210 (US). (74) Agent: WILLIAMS, Joseph, A., Jr.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606-6402 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 27 April 2000 (27.04.00)
(54) Title: METHODS FOR MODULATING DIFFERENTIATION (57) Abstract <p>This invention generally relates to materials and methods for modulating the differentiation of cells. Specifically provided are methods to promote or inhibit cell differentiation and methods to identify compounds that promote cellular differentiation.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/09102

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N5/10 C12N15/85 C12N9/12 C12N15/54 C12N15/12
C07K14/47 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 97 09433 A (MEDICAL RES COUNCIL ;CARR ANTONY MICHAEL (GB)) 13 March 1997 (1997-03-13)</p> <p>abstract page 6, line 25 -page 9, line 2 page 16, line 10 -page 26, line 3 page 27, line 23 -page 30, line 33 page 2, line 15 -page 3, line 22</p> <p style="text-align: center;">-/-</p>	<p>1,2,4-6, 8-12, 15-17, 22-24, 31-34, 41-46,49</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 March 2000

Date of mailing of the international search report

15/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 940-2040, Tx. 91 651 epo nl,
Fax: (+31-70) 940-9016

Authorized officer

Mateo Rosell, A.M.

INTERNATIONAL SEARCH REPORT

Inter. Patent Application No.
PCT/US 99/09102

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FIDDLER T A ET AL: "Amplification of MDM2 inhibits MyoD-mediated myogenesis" MOLECULAR AND CELLULAR BIOLOGY,US,WASHINGTON, DC, vol. 16, no. 9, September 1996 (1996-09), pages 5048-5057-5057, XP002110694 ISSN: 0270-7306 cited in the application the whole document	1,2,4,5, 8-12, 15-19, 22-25, 31,32, 34-40, 45,46, 48,49
X	KATAYOSE D ET AL: "CONSEQUENCES OF P53 GENE EXPRESSION BY ADENOVIRUS VECTOR ON CELL CYCLE ARREST AND APOPTOSIS IN HUMAN AORTIC VASCULAR SMOOTH MUSCLE CELLS" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 215, no. 2, 13 October 1995 (1995-10-13), pages 446-451, XP000619244 ISSN: 0006-291X the whole document	1,2,5, 8-10,12, 15-17,19
X	AGARWAL M L ET AL: "p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 92, no. 92, August 1995 (1995-08), pages 8493-8497-8497, XP002108341 ISSN: 0027-8424 abstract	1,2, 8-10, 15-17, 22-24, 31-33, 45,46
X	SANCHEZ Y ET AL: "Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25 'see comments!'" SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 277, no. 5331, 5 September 1997 (1997-09-05), pages 1497-1501, XP002087723 ISSN: 0036-8075 the whole document	1,2,7
	-/-	

INTERNATIONAL SEARCH REPORT

Int. Appl. No.
PCT/US 99/09102

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>FLAGGS G ET AL: "Atm-dependent interactions of a mammalian chk1 homolog with meiotic chromosomes" CURRENT BIOLOGY,GB,CURRENT SCIENCE,, vol. 7, no. 12, 1 December 1997 (1997-12-01), pages 977-986, XP002087728 ISSN: 0960-9822 cited in the application the whole document</p>	1,7,31, 34
A	<p>CARR A M ET AL: "THE CELLULAR RESPONSES TO DNA DAMAGE" TRENDS IN CELL BIOLOGY,ELSEVIER SCIENCE LTD, vol. 5, 1 January 1995 (1995-01-01), pages 32-40, XP000616350 ISSN: 0962-8924 the whole document</p>	1
A	<p>CARR A M: "Checkpoints take the next step 'comment!'" SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 271, no. 5247, 19 January 1996 (1996-01-19), pages 314-315, XP002087726 ISSN: 0036-8075</p>	1
A	<p>WEINERT T: "A DNA damage checkpoint meets the cell cycle engine 'comment!'" SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 277, no. 5331, 5 September 1997 (1997-09-05), pages 1450-1451, XP002087727 ISSN: 0036-8075</p>	1
P,X	<p>SMITH L. ET AL., : "Duplication of ATR inhibits MyoD, induces aneuploidy and eliminates radiation-induced G1 arrest" NATURE GENETICS, vol. 19, no. 1, May 1998 (1998-05), pages 39-46, XP000884862 the whole document</p>	1,2,4-6, 8-13, 15-20, 22-25, 29,34-50
P,X	<p>WO 99 11795 A (CARR ANTONY MICHAEL ;ICOS CORP (US)) 11 March 1999 (1999-03-11)</p> <p>abstract page 6, line 26 -page 15, line 15; examples 1-6 claims 21,22</p>	1,2,4,5, 7-12, 14-19, 21-25, 30-50

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 99/09102

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9709433 A	13-03-1997	AU 6884696 A	27-03-1997
		BR 9610168 A	11-08-1998
		CA 2231190 A	13-03-1997
		CN 1201492 A	09-12-1998
		EP 0856058 A	05-08-1998
		JP 11511984 T	19-10-1999
		NO 980957 A	05-05-1998
		PL 325427 A	20-07-1998
WO 9911795 A	11-03-1999	AU 9223198 A	22-03-1999
		EP 0960203 A	01-12-1999

Form PCT/ISA/210 (patent family annex) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)